InvestSMART

ORDINARY FULLY PAID (ASX: OPT) - Announcements

DELISTED - Current share price for OPT : $0.013

ASX company news and announcements for ORDINARY FULLY PAID (OPT) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All ORDINARY FULLY PAID (OPT) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than ORDINARY FULLY PAID (OPT), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for ORDINARY FULLY PAID (OPT)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$18 Opthea to Appoint Dr Jeremy Levin as Chairman of the Board 5 Oct 2020 10:47AM $2.810 $0.013 fallen by 99.54%
$18 Ceasing to be a substantial holder 29 Sep 2020 6:20PM $2.900 $0.013 fallen by 99.55%
$18 Opthea Files Registration Statement for Proposed US IPO 25 Sep 2020 8:20AM $2.840 $0.013 fallen by 99.54%
$18 Change in substantial holding 23 Sep 2020 6:01PM $2.910 $0.013 fallen by 99.55%
$18 Change in substantial holding 22 Sep 2020 8:17AM $2.900 $0.013 fallen by 99.55%
$18 Initial Director's Interest Notice - DS 15 Sep 2020 9:49AM $2.860 $0.013 fallen by 99.55%
$18 Notice of Annual General Meeting and Proxy Form 11 Sep 2020 9:29AM $2.750 $0.013 fallen by 99.53%
$18 Appendix 4G and Corporate Governance Statement 2020 11 Sep 2020 9:26AM $2.750 $0.013 fallen by 99.53%
$18 Annual Report 2020 11 Sep 2020 9:24AM $2.750 $0.013 fallen by 99.53%
$18 Opthea Appoints US-Based Non-Executive Director 10 Sep 2020 9:19AM $2.770 $0.013 fallen by 99.53%
$18 Opthea Full Year Financial Report 2020 28 Aug 2020 9:00AM $2.490 $0.013 fallen by 99.48%
$18 Opthea Announces Plans for Potential US listing and IPO 24 Aug 2020 8:30AM $2.550 $0.013 fallen by 99.49%
$18 Opthea Completes Successful FDA and EMA Meetings for Phase 3 21 Aug 2020 9:18AM $2.330 $0.013 fallen by 99.44%
$18 Opthea Key Opinion Leader Symposium Presentation 6 Aug 2020 11:04AM $2.450 $0.013 fallen by 99.47%
$18 Opthea to Host Key Opinion Leader Symposium on wAMD and DME 28 Jul 2020 9:10AM $2.620 $0.013 fallen by 99.50%
$18 Initial Director's Interest Notice - LG 27 Jul 2020 5:31PM $2.620 $0.013 fallen by 99.50%
$18 Corporate Presentation of Ph1b/2a DME Trial Data (ASRS) 27 Jul 2020 8:55AM $2.720 $0.013 fallen by 99.52%
$18 Opthea Presents New Data from Ph 1b/2a DME Trial at ASRS 27 Jul 2020 8:50AM $2.720 $0.013 fallen by 99.52%
$18 Opthea Appoints New Non-Executive Director 24 Jul 2020 9:06AM $2.670 $0.013 fallen by 99.51%
$18 Opthea to Present OPT-302 DME Clinical Data at ASRS 2020 23 Jul 2020 9:36AM $2.300 $0.013 fallen by 99.43%
$18 Change in substantial holding 26 Jun 2020 6:53PM $2.480 $0.013 fallen by 99.48%
$18 Change in substantial holding 22 Jun 2020 6:43PM $2.830 $0.013 fallen by 99.54%
$18 Opthea Added to the S&P/ASX 300 Index 22 Jun 2020 8:41AM $2.740 $0.013 fallen by 99.53%
$18 S&P DJI Announces June 2020 Quarterly Rebalance 12 Jun 2020 8:16AM $2.610 $0.013 fallen by 99.50%
$18 Opthea Reports Positive Ph2a Trial Results of OPT-302 in DME 10 Jun 2020 8:47AM $3.360 $0.013 fallen by 99.61%

501 - 525 of 733 results

Page 21 of 30

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.